Single Gene Mutations Drive Diverse Cancer Paths, Study Finds

The understanding of cancer is undergoing a subtle but significant shift. For years, it’s been broadly categorized as a single disease, but emerging research reveals a far more nuanced reality. Even tumors within the same organ can behave differently and a new study published in Nature Genetics suggests these variations can be traced back to the strength of mutations within a single gene, rather than simply the presence or absence of a mutation.

The CTNNB1 Gene and β-catenin Signaling

The gene at the heart of this discovery is CTNNB1, which provides the instructions for creating a protein called β-catenin. β-catenin plays a crucial role in cell growth, but its activity needs to be tightly regulated. Normally, a cellular “destruction complex” keeps β-catenin levels in check by tagging it for removal. When this system malfunctions – either due to mutations in the destruction complex itself or changes directly within CTNNB1 – β-catenin accumulates and triggers genes that promote cell growth. This hijacking of normal biological processes is a hallmark of cancer development. Researchers have long known that CTNNB1 mutations are common in many cancers, but this new work demonstrates that not all mutations are created equal.

Saturation Genome Editing Reveals a Spectrum of Mutation Strength

Led by Dr. Derya Deniz Özdemir from Koç University School of Medicine and the Research Centre for Translational Medicine (KUTTAM), along with teams from the University of Edinburgh and UMC Leiden, the study employed a powerful technique called saturation genome editing. This method allowed researchers to systematically test every possible mutation within a critical region of CTNNB1, known as the “degron hotspot.” Instead of examining one mutation at a time, they introduced all 342 possible changes into mouse stem cells simultaneously and measured how strongly each mutation activated β-catenin signaling. The result was a detailed map showing that these mutations range from barely detectable increases in signaling to dramatically heightened activation. The study, published February 5, 2026, provides a comprehensive view of the spectrum of effects these mutations can have.

“Just-Right” Signaling and Tissue-Specific Mutation Selection

One of the most intriguing findings is that tumors in different parts of the body don’t randomly select mutations. Instead, each tissue appears to favor mutations that push β-catenin signaling to a specific level – a concept the researchers refer to as “just-right” signaling. This suggests that there’s an optimal level of β-catenin activity for tumor growth in each tissue type. Too little signaling might not be enough to drive cancer development, although too much could trigger other cellular defenses or limit the tumor’s ability to thrive. This finding challenges the traditional view of cancer mutations as simply “on” or “off” switches, highlighting the importance of the degree of mutation strength.

Implications for Understanding Cancer Behavior

This research doesn’t immediately change cancer treatment, but it offers a crucial new lens through which to understand how tumors develop and behave. It suggests that focusing solely on identifying which genes are mutated may not be enough. Understanding the strength of those mutations – how much they alter the function of the protein – could be equally important. This could potentially lead to more targeted therapies that specifically address the level of β-catenin signaling in a particular tumor. It likewise opens up possibilities for developing biomarkers that can predict how a tumor will respond to treatment based on the specific CTNNB1 mutation it carries.

The Role of the Immune System

The study also hints at a connection between mutation strength and the immune system. The researchers found that the level of β-catenin signaling influenced how effectively the immune system could recognize and attack tumor cells. This suggests that mutations that lead to “just-right” signaling might assist tumors evade immune detection, allowing them to grow unchecked. Further research is needed to fully understand this interplay, but it highlights the potential for immunotherapies to be tailored based on the specific CTNNB1 mutation present in a tumor.

What Comes Next: Refining Cancer Therapies and Predictive Biomarkers

The findings from Dr. Özdemir’s team are likely to spur further investigation into the role of mutation strength in other cancer-related genes. Researchers will need to explore whether the “just-right” signaling concept applies to other pathways and tissues. Dr. Özdemir and her colleagues are continuing to investigate the mechanisms by which different CTNNB1 mutations affect tumor behavior and immune response. The ultimate goal is to translate these findings into more effective cancer therapies and more accurate predictive biomarkers. Clinical trials will be essential to determine whether therapies targeting β-catenin signaling based on mutation strength can improve patient outcomes. Ongoing surveillance of cancer genomes will also be crucial to identify patterns of mutation selection in different tissues and populations.

This research underscores the complexity of cancer and the importance of moving beyond a one-size-fits-all approach to treatment. By focusing on the nuances of mutation strength, scientists are paving the way for a more personalized and effective fight against this devastating disease.